Samarth Kulkarni
2020
In 2020, Samarth Kulkarni earned a total compensation of $9.1M as Chief Executive Officer at CRISPR Therapeutics AG, a 44% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $543,750 |
---|---|
Option Awards | $6,343,596 |
Salary | $625,000 |
Stock Awards | $1,585,785 |
Other | $7,125 |
Total | $9,105,256 |
Kulkarni received $6.3M in option awards, accounting for 70% of the total pay in 2020.
Kulkarni also received $543.8K in non-equity incentive plan, $625K in salary, $1.6M in stock awards and $7.1K in other compensation.
Rankings
In 2020, Samarth Kulkarni's compensation ranked 970th out of 13,090 executives tracked by ExecPay. In other words, Kulkarni earned more than 92.6% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 970 | 93rd |
Manufacturing | 341 | 94th |
Chemicals And Allied Products | 116 | 95th |
Drugs | 102 | 95th |
Biological Products, Except Diagnostic Substances | 26 | 94th |
Kulkarni's colleagues
We found four more compensation records of executives who worked with Samarth Kulkarni at CRISPR Therapeutics AG in 2020.
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019